drugset / Trial / NCT07413133

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

NCT07413133

Phase 1 Completed 40 enrolled AbbVie
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Timeline

Start
2026-02-11
Primary completion
2026-06-19
Completion
2026-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-8736 Unknown Intravenous

Indications

No indication recorded.